Last reviewed · How we verify
NCT03067584
Genetic Study of Familial Acute Lymphoblastic Leukemia
trial in Acute Lymphoblastic Leukemia (ALL) in 4 participants. Completed in 23 June 2017.
23 June 2017
Quick facts
| Lead sponsor | St. Jude Children's Research Hospital |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 4 |
| Start date | 9 May 2017 |
| Primary completion | 23 June 2017 |
| Estimated completion | 23 June 2017 |
| Sites | 1 location across United States |
Conditions studied
- Acute Lymphoblastic Leukemia (ALL) — all drugs for Acute Lymphoblastic Leukemia (ALL) →
Sponsor
St. Jude Children's Research Hospital
Who can join
Eligibility, any sex, with Acute Lymphoblastic Leukemia (ALL). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Familial aggregation is well recognized in some cancers. Though a number of familial cancer predisposition syndromes have been described, the nature of inherited genetic alterations in patients with a strong history of familial cancer is currently unknown, as is the case with childhood acute lymphoblastic leukemia (ALL). The investigators are seeking to learn more about what causes leukemia and why some people and families may be at a higher risk of developing this disease. By understanding the origin of the disease, better treatments may be identified for patients with leukemia. PRIMARY OBJECTIVE: To identify variants in genes that are inherited, have altered gene structure and/or function, and influence the risk of developing acute lymphoblastic leukemia (ALL) and other cancers. SECONDARY OBJECTIVE: To collect demographic, clinical and laboratory information including detailed family cancer history and response of cancers to therapy for correlation with the primary objective.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Unraveling the Genetic Heterogeneity of Acute Lymphoblastic Leukemia Based on NGS Applications.
Ramírez Maldonado V, Navas Acosta J, Maldonado Marcos I, Villaverde Ramiro Á, et al · · 2024 · cited 1× · PMID 39682152 · DOI 10.3390/cancers16233965
Verify or expand the search:
- PubMed search for NCT03067584
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Acute Lymphoblastic Leukemia (ALL)
Currently open trials in the same condition.
- NCT07246213 — CAYA Cancer Retrospective Cohort Study · recruiting
- NCT05884333 — Cord Blood Transplant in Adults With Blood Cancers · Phase 2 · recruiting
- NCT03849651 — TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-ce · Phase 2 · active not recruiting
- NCT03590171 — International Study for Treatment of High Risk Childhood Relapsed ALL 2010 · Phase 2 · recruiting
- NCT02790515 — Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical · Phase 2 · active not recruiting
Other St. Jude Children's Research Hospital trials
Trials by the same sponsor.
- NCT07222735 — Hypofractionated Radiation in Combination With B7-H3-CAR T Cells for Pediatric Patients With Relapsed/Refractory Sarcoma · Phase 1 · recruiting
- NCT07085338 — A Phase II Study With a Safety Run-In of the Addition of N-803 to a Chemoimmunotherapy Backbone for the Treatment of Pat · Phase 2 · recruiting
- NCT05664113 — Feasibility, Safety, and Potential Efficacy of Fecal Microbiota Transplantation (FMT) for Gastrointestinal Dysfunction i · Phase 1 · recruiting
- NCT06993688 — Revealing Information Genuinely & Honestly Across Time - Communication Preferences Visit · NA · recruiting
- NCT06326463 — CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies · Phase 1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03067584 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by St. Jude Children's Research Hospital
- Last refreshed: 11 December 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03067584.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing